Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

[Current management of type 2 diabetes in France].

Jaffiol C.

Bull Acad Natl Med. 2009 Oct;193(7):1645-61. Review. French.

PMID:
20669642
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
4.

[Management of patients with type 2 diabetes. Results in 12 practices of general practitioners].

Rothenbacher D, Rüter G, Saam S, Brenner H.

Dtsch Med Wochenschr. 2002 May 31;127(22):1183-7. German.

PMID:
12035113
5.

Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey.

Charpentier G, Genès N, Vaur L, Amar J, Clerson P, Cambou JP, Guéret P; ESPOIR Diabetes Study Investigators..

Diabetes Metab. 2003 Apr;29(2 Pt 1):152-8.

PMID:
12746636
6.
7.

Epidemiology and costs of diabetes treated with insulin in France.

Detournay B, Raccah D, Cadilhac M, Eschwège E.

Diabetes Metab. 2005 Jun;31(3 Pt 2):3-18.

PMID:
16142041
8.

[Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].

Fabian W, Majkowska L, Stefański A, Moleda P.

Przegl Lek. 2005;62(4):201-5. Polish.

PMID:
16229234
9.

Prevalence of macrovascular complications and cardiovascular risk factors in people treated for diabetes and living in France: the ENTRED study 2001.

Romon I, Fosse S, Eschwège E, Simon D, Weill A, Varroud-Vial M, Detournay B, Fagot-Campagna A.

Diabetes Metab. 2008 Apr;34(2):140-7. doi: 10.1016/j.diabet.2007.11.002. Epub 2008 Mar 4.

PMID:
18304854
10.
11.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

12.

Type II diabetes mellitus.

Edelman SV.

Adv Intern Med. 1998;43:449-500. Review.

PMID:
9506190
13.

Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory.

Monnier L, Grimaldi A, Charbonnel B, Iannascoli F, Lery T, Garofano A, Childs M; Mediab..

Diabetes Metab. 2004 Feb;30(1):35-42.

PMID:
15029096
15.

Treatment of metabolic syndrome.

Wagh A, Stone NJ.

Expert Rev Cardiovasc Ther. 2004 Mar;2(2):213-28. Review.

PMID:
15151470
16.

[Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].

Schiel R, Müller UA, Stein G.

Med Klin (Munich). 2005 Aug 15;100(8):453-61. German.

PMID:
16096726
17.

Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America.

Lopez Stewart G, Tambascia M, Rosas Guzmán J, Etchegoyen F, Ortega Carrión J, Artemenko S.

Rev Panam Salud Publica. 2007 Jul;22(1):12-20.

PMID:
17931483
18.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746
19.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
20.

How should we treat type 2 diabetes in youth?

Urakami T.

Pediatr Endocrinol Rev. 2005 Sep;3(1):33-9. Review.

PMID:
16369211

Supplemental Content

Support Center